<DOC>
	<DOCNO>NCT02256800</DOCNO>
	<brief_summary>Metastatic disease find 20-25 % patient initial diagnosis colorectal cancer develop 50 % patient . Owing limited post-treatment response 5-fluorouracil ( 5-FU ) combine leucovorin ( LV ) obtain mCRC ( metastatic colorectal cancer ) patient , therapeutic agent different mechanism consider , irinotecan , potent inhibitor topoisomerase I , involve unwinding DNA replication . Bevacizumab humanize monoclonal antibody inhibits tumor angiogenesis block vascular endothelial growth factor ( VEGF ) first antiangiogenic agent approve treatment cancer . Infusional fluorouracil/leucovorin plus irinotecan-based regimen ( FOLFIRI ) bevacizumab widely use first-line treatment patient metastatic colorectal cancer ( mCRC ) . Recently , investigator show prospective analysis uridine diphosphate glucuronosyl transferase 1A1 ( UGT1A1 ) genotyping irinotecan dose escalation ( FOLFIRI regimen ) combination bevacizumab biweekly first-line setting mCRC patient ( ASCO Abstract # 491 - 2013 Gastrointestinal Cancers Symposium ) . In study , investigator enroll approximately 320 mCRC patient ( It consider increase response rate 15 % compare conventional irinotecan dose 180 mg/m2 , choose parameter calculate study power . Initial power calculation suggest minimum 140 patient group would require achieve statistical significance power 80 % 5 % significance level . It estimate 10 % 320 mCRC patient fail complete study ) . For enrolled patient , investigator randomize divide patient two group : control group study group . Control group include mCRC patient receive conventional regimen FOLFIRI plus bevacizumab . Otherwise , patient study group genotyping UGT1A1 therapy , dose escalate irinotecan depend result genotyping .</brief_summary>
	<brief_title>Prospective Analysis UGT1A1 Promoter Polymorphism Irinotecan Dose Escalation Metastatic Colorectal Cancer Patients Treated With Bevacizumab Combined With FOLFIRI First-line Setting</brief_title>
	<detailed_description>Control group : Regimen treatment consist bevacizumab ( Avastin ) 5mg/Kg ( IV infusion ) day 1 , follow irinotecan ( 180 mg/m2 120-min IV infusion ) , LV ( 400 mg/m2 IV infusion 2 hour ) , 5-FU ( 2800 mg/m2 IV infusion 46-hour period ) , repeat every 2 week . Study group : FOLFIRI ( infusional fluorouracil/leucovorin plus irinotecan ) + Bevacizumab . The dosage irinotecan adjust UGT1A1 genotyping The wild-type ( 6/6 ) UGT1A1 : Regimen treatment consist bevacizumab ( Avastin ) 5mg/Kg ( IV infusion ) day 1 , follow irinotecan ( 180 mg/m2 120-min IV infusion ) , LV ( 400 mg/m2 IV infusion 2 hour ) , 5-FU ( 2800 mg/m2 IV infusion 46-hour period ) , repeat every 2 week . After 2 cycle different dose irinotecan , observe adverse effect ( AEs ) hematological / non-hematological . If grade grade 2 , escalate dose 30 mg/m2 gradually . The estimate maximal dose irinotecan 260 mg/m2 . The ( 6,7 ) type UGT1A1 : Regimen treatment consist bevacizumab ( Avastin ) 5mg/Kg ( IV infusion ) day 1 , follow irinotecan ( 180 mg/m2 120-min IV infusion ) , LV ( 400 mg/m2 IV infusion 2 hour ) , 5-FU ( 2800 mg/m2 IV infusion 46-hour period ) , repeat every 2 week . After 2 cycle different dose irinotecan , observe adverse effect ( AEs ) hematological / non-hematological . If grade grade 2 , escalate dose 30 mg/m2 gradually . The estimate maximal dose irinotecan 240 mg/m2 . The ( 7,7 ) type UGT1A1 : Regimen treatment consist bevacizumab ( Avastin ) 5mg/Kg ( IV infusion ) day 1 , follow irinotecan ( 120 mg/m2 120-min IV infusion ) , LV ( 400 mg/m2 IV infusion 2 hour ) , 5-FU ( 2800 mg/m2 IV infusion 46-hour period ) , repeat every 2 week . After 2 cycle different dose irinotecan , observe adverse effect ( AEs ) hematological / non-hematological . If grade grade 2 , escalate dose 30 mg/m2 gradually . The estimate maximal dose irinotecan 180 mg/m2 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . 20 y/o ≦ Age ≦ 80y/o 2 . Either metachronous synchronous mCRC enrol 3 . Female patient need ready pregnant breastfeed 4 . No major underlie disease ( cardiovascular , cerebrovascular , malignant hypertension , kidney , liver major disease ) 5. mCRC proven pathologist radiologists 6 . Subjects willing sign inform consent form Patients meet include criterion unwilling participate</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>